Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

CRANBURY, N.J., Feb. 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2012.  Palatin reported a net loss of $1.7 million, or $(0.02) per basic and diluted share, for the quarter ended December 31, 2012, compared to a net loss of $2.6 million, or $(0.08) per basic and diluted share, for the same period in 2011. 

The decrease in net loss for the quarter ended December 31, 2012, compared to the same period last fiscal year, is primarily attributable to an increase in net proceeds from the sale of New Jersey state net operating loss carryforwards, which resulted in the recognition of $1.8 million and $1.1 million, respectively, in tax benefits for the three months ended December 31, 2012 and 2011, and secondarily to a decrease in operating expenses for the periods presented.

REVENUE
Revenues, which consisted of contract revenue pursuant to the collaboration agreement with AstraZeneca, were $6,555 for the quarter ended December 31, 2012 compared to $11,492 for the quarter ended December 31, 2011.

COSTS AND EXPENSES
Total operating expenses for the quarter ended December 31, 2012 were $3.4 million compared to $3.7 million for the comparable quarter of 2011.  The decrease in operating expenses for the quarter was primarily due to lower costs related to Palatin's Phase 2B clinical trial with bremelanotide for Female Sexual Dysfunction (FSD), which Palatin reported positive top-line results on November 8, 2012.

CASH POSITION
Palatin's cash and cash equivalents were $32.9 million as of December 31, 2012, compared to $3.8 million at June 30, 2012, with current liabilities of $2.0 million as of December 31, 2012 compared to $3.5 million as of June 30, 2012
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 Cambrex Corporation (NYSE: CBM ... 2014. Highlights , Second quarter ... the same period last year. , Second quarter EBITDA ... the same period last year (see table at the end ... increased, excluding the impact of foreign currency, to between 13% ...
(Date:7/31/2014)... 2014 Food and natural product ... for food alternatives that offer variety, as well ... ingredient market has numerous players operating in the ... Force Technology (VFT). VFT is a science-driven ... patterns, all tested to produce stable, effective and ...
(Date:7/31/2014)... July 31, 2014 Nearly 20,000 medical professionals ... Annual Meeting & Clinical Lab Expo in ... never-before-seen breakthroughs in diagnostic research and technology that will ... As of Wednesday, July 30, more than ... Meeting & Clinical Lab Expo, with more than 10,000 ...
(Date:7/31/2014)... see through organs and even the entire body to ... cellular structures has been a long-time dream of biologists. ... 31st in the journal Cell has now ... making opaque organs, bodies, and human tissue biopsies transparent, ... protocols could pave the way for a better understanding ...
Breaking Biology Technology:Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3See-through organs and bodies will accelerate biomedical discoveries 2
... Meeting, DEERFIELD, Ill., May 6 The Board ... today announced a quarterly,dividend and votes taken at the ... Board of Directors declared a quarterly dividend of $0.2175,per ... continuation of,the current rate. The quarterly dividend is payable ...
... May 6 Sigma-Aldrich Corporation,(Nasdaq: SIAL ) will ... on Tuesday, May 13th at 10:40 AM Pacific Time ... audio broadcast over the,Internet available at http://ir.sigmaaldrich.com . ... For the webcast on, http://ir.sigmaaldrich.com users will need ...
... May 6 There are a lot of steps,between ... organization,s,sales force must be involved with many of those ... successful re-launch effort,according to a study by benchmarking leader ... sales force? Half of the companies that,participated in the ...
Cached Biology Technology:Invigorated Sales Force Key to a Successful Re-Launch 2
(Date:7/31/2014)... noise alters how the brain processes speech, potentially ... to neuroscientists at The University of Texas at ... in Ear and Hearing , researchers demonstrated ... affects the brain,s recognition of speech sounds. , ... the population, affecting an estimated 15 percent of ...
(Date:7/31/2014)... The enormous conflagration known as the Rim Fire was ... among mature trees, when it entered the backcountry of ... August 2013. But inside the park, the battle began ... management decisions and drought can combine to fuel large, ... park, it eventually encountered lands where fire had been ...
(Date:7/31/2014)... or fat cells, are inherently different. Each of these ... own role in metabolism. In the human body, white ... primary function is energy storage. On the other hand, ... are only found in a few places in the ... type of brown adipocytes, appear mixed with brown adipocytes ...
Breaking Biology News(10 mins):UT Dallas study reveals effect of loud noises on brain 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Hope for the overweight 2
... researchers have discovered that the Chlamydia bacterium, which causes ... with plants. That shared evolutionary heritage, which is not ... target for development of an effective cure for Chlamydia ... and plants had been proposed by others," said Thomas ...
... administered intravenously could be used as an agent to ... ionizing radiation in the event of large-scale exposure from ... study presented today by University of Pittsburgh researchers at ... Therapeutic Radiology and Oncology (ASTRO) in Philadelphia. , "Ionizing ...
... since the development of highly active antiretroviral therapy (or HAART) ... do so well that, according to blood tests, their immune ... studies from Rockefeller University and the Aaron Diamond AIDS Research ... tissues may never rebound, suggesting the need for additional ways ...
Cached Biology News:Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia 2Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia 3Intravenous gene therapy protects normal tissue of mice during whole-body radiation 2HIV-1 kills immune cells in the gut that may never bounce back 2HIV-1 kills immune cells in the gut that may never bounce back 3